The crucial role of the NADPH oxidase complex is emphasized by the remarkable susceptibility to IPA in patients with chronic granulomatous disease (CGD), a condition characterized by genetic deficiency in components of the NADPH oxidase complex. Here, FMO5 is linked to chronic granulomatous disease.